Which pharmaceutical company developed the diabetes and obesity drug Ozempic?

Novo Nordisk developed Ozempic, the brand name for a semaglutide medicine used to treat adults with type 2 diabetes.

Novo Nordisk is a Danish pharmaceutical company specializing in diabetes care, obesity treatment, and related chronic diseases. Ozempic was approved in the United States in 2017 for improving blood-sugar control in adults with type 2 diabetes, alongside diet and exercise.

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. It imitates a naturally occurring hormone involved in blood-glucose regulation and appetite signaling. Novo Nordisk also markets semaglutide under other brand names and for different approved uses, but those products should not be treated as interchangeable in every context.

A frequent mix-up is confusing Ozempic with Eli Lilly's tirzepatide products. Both companies make prominent metabolic medicines, yet Ozempic is specifically associated with Novo Nordisk and semaglutide. The company's strong position in these markets helped make it a major high-market-cap pharmaceutical business.